Although cancer cell fusion has been suggested as a mechanism of cancer metastasis, the underlying mechanisms defining this process are poorly understood. In a recent study, apoptotic cells were newly identified as a type of cue that induces signaling via phosphatidylserine receptors to promote fusion of myoblasts. The microenvironment of breast tumors is often hypoxic, and because apoptosis is greatly increased in hypoxic conditions, we decided to investigate whether the mechanism of breast cancer cell fusion with mesenchymal stem/multipotent stromal cells (MSCs) involves apoptosis. We used a powerful tool for identification and tracking of hybrids based on bimolecular fluorescence complementation (BiFC) and found that breast cancer cells fused spontaneously with MSCs. This fusion was significantly enhanced with hypoxia and signaling associated with apoptotic cells, especially between nonmetastatic breast cancer cells and MSCs. In addition, the hybrids showed a significantly higher migratory capacity than did the parent cells. Taken together, these findings describe a mechanism by which hypoxiainduced apoptosis stimulates fusion between MSCs and breast tumor cells resulting in hybrids with an enhanced migratory capacity that may enable their dissemination to distant sites or metastases. In the long run, this study may provide new strategies for developing novel drugs for preventing cancer metastasis.-Noubissi, F. K., Harkness, T., Alexander, C. M., Ogle, B. M. Apoptosis-induced cancer cell fusion: a mechanism of breast cancer metastasis. FASEB J. 29, 000-000 (2015). www.fasebj.org
FUSION OF BREAST CANCER CELLS with cells of the tumor microenvironment has been proposed as a means of generating widespread genetic and epigenetic diversity (1) (2) (3) (4) . Diversity created in this way could rapidly enhance the formation, propagation, and metastasis of tumor cells or could quickly alter drug sensitivity. Yet to be reconciled are the precise mechanisms governing hybrid reprogramming after cell fusion and the means by which cancer cells undergo spontaneous fusion in the first place. The latter was the focus of this work.
One way that spontaneous cell fusion is enabled is via specific integral membrane proteins, termed fusogens, which provide cell anchorage and disrupt cell membranes, to minimize the energy necessary to overcome the merger of the 2 hydrophobic membranes (5) . The structure and function of many viral fusogens are well characterized, but eukaryotic fusogens are more difficult to establish because removal of facilitating proteins from the system reduces overall fusion rates. As technologies advance, many putative fusogens have been contested and shown to be merely adhesion proteins that bring cell membranes in close apposition but do not actually facilitate fusion. Take, for example, heterotypic gamete fusion. As a fusion product, the fertilized embryo can proliferate and differentiate into all the tissues of the adult body as well as the extraembryonic tissues. CD9 is an egg-associated putative fusogen. Cluster of differentiation (CD)9-knockout mice have shown severely hampered fertilization (6) that is restored with polyadenylated CD9 mRNA (7) . In addition, CD9 has been shown to generate the strongest observed interactions with the sperm (8) . However, it is not known whether it specifically facilitates the disruption and merging of membranes or whether other facilitating proteins or conditions are necessary (5) .
Bona fide fusogens may not be necessary for cell fusion if cell membranes can be disrupted by other means. Cell stress, including nutrient deprivation, electroporation, and hypoxia, can render cell membranes leaky or unstable (9) (10) (11) . For example, changes in the ratio of cholesterol to phospholipid and in the double-bond index of the associated fatty acids have been shown to alter plasma membrane structure during hypoxic injury (12) . In addition, alterations in lipid structure with hypoxia can lead to changes in membrane protein structure and function, resulting in dysregulated enzyme activity and transport properties that could also lead to leakiness of the plasma membrane barrier (13) . Unstable cell membranes are biophysically Abbreviations: aMEM, a-minimum essential medium; BAI, brain-specific angiogenesis inhibitor; BiFC, bimolecular fluorescence complementation; CCL, chemokine ligand; CD, cluster of differentiation; CMV, cytomegalovirus; COI, cytochrome c oxidase I; Dock, dedicator of cytokines; EBV, EpsteinBarr virus; ELMO, engulfment cell and mobility protein; GFP, (continued on next page) susceptible to membrane fusion (14, 15) . It may be for this reason that cell fusion appears to occur more readily in the context of hypoxia than during normoxia (16, 17) . In contrast, cell fusion may be enhanced with hypoxia via signaling events triggered by hypoxic stress. For example, human hematopoietic progenitor cells upregulate VCAM-1 with hypoxia, a protein found to enhance adhesion and fusion with cardiomyocytes. Similarly, fusion of skeletal myocytes is increased during hypoxia, in part because of signaling events associated with apoptotic cells. Apoptotic cells exhibit exposed phosphatidyl serine and choline, which binds associated phosphatidyl serine and choline receptors expressed by skeletal muscle. Binding of these receptors in skeletal muscle can engage the engulfment cell and mobility protein (ELMO)/dedicator of cytokines (Dock)180/ras-related C3 botulinum toxin substrate (Rac)-1 module to enhance myoblast fusion (18) . To accurately test whether apoptotic cells enable cell fusion, we used a unique tool developed in our lab to detect fusion products that was based on bimolecular fluorescence complementation (BiFC). With this approach, a fluorescent signal is induced by hybrid formation and can be detected in living cells. In addition, the signal intensity in hybrids increases over time as BiFC products are continuously synthesized. Using this robust tool, we showed that spontaneous fusion of multipotent stem/stromal cells (MSCs) with breast cancer cells occurs more readily in hypoxia than in normoxia, a significant finding, given that the microenvironment of breast tumors is often hypoxic. In addition, we found that, like skeletal muscle, cell fusion with hypoxia is enhanced as a consequence of the signaling associated with apoptotic cells. These findings are among the first to address how cancer cells spontaneously fuse in the first place and, as a consequence, reveal novel untapped therapeutic targets.
MATERIALS AND METHODS

Cell lines and culture
MSCs were a generous gift from Dr. Peiman Hematti (University of Wisconsin, Madison, WI, USA). They were derived from human embryonic stem cells in accordance with guidelines of the University of Wisconsin Institutional Review Board (19) and maintained in a-minimum essential medium (Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT, USA). We reconfirmed the identity of the MSCs in our lab by flow cytometry for specific MSC markers. Human mammary epithelial cells (MCF10a), human ductal breast epithelial tumor cells (T47D), human breast adenocarcinoma cells (MDA-MB-231), and human breast cancer cells (MCF7) (MCF indicates the Michigan Cancer Foundation where the MCF10a and MCF7 lines were established) were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in accordance with the recommendations of ATCC; the cells were not passaged for more than 6 mo from the time of receipt. MCF10as were tested for: 1) mycoplasma by DNA stain and agar culture, 2) species determination by short tandem repeat (STR) analysis and cytochrome c oxidase I (COI) assay, 3) sterility by BacT/ALERT 3D (bioMérieux, St. Louis, MO, USA), and 4) the human pathogens HIV, hepatitis B and C (HepB, HepC), human papilloma virus (HPV), Epstein Barr virus (EBV), and cytomegalovirus (CMV). T47Ds were tested for: 1) mycoplasma by DNA stain and agar culture, 2) species determination by STR and COI assays, and 3) sterility by BacT/ ALERT 3D. MDA-MB-231s were tested for: 1) mycoplasma by DNA stain and agar culture, 2) species determination by STR and COI assay, 3) sterility by BacT/ALERT 3D, and 4) the human pathogens listed above. MCF7s were tested for: 1) mycoplasma by DNA stain and agar culture, 2) species determination by STR, 3) sterility by BacT/ALERT 3D, and 4) the human pathogens listed above.
BiFC approach
BiFC is a method of viewing living hybrid cells (20, 21 ) (Supplemental Fig. S1A ). Thus, the fluorescence of green fluorescent protein (GFP) is reconstituted when 2 nonfluorescent halves, expressed in fusion partners, are coexpressed and are in proximity in fusion products (22) (23) (24) (25) (26) . To encourage proximity, each nonfluorescent half is coupled to histone 3.1 (H3.1; plasmids, a generous gift of Dr. Thomas Kerppola, University of Michigan, Ann Arbor, MI, USA). Fluorescence was detected and recorded via traditional fluorescence microscopy (excitation 485, emission 530; Olympus IX81; Olympus America, Center Valley, PA, USA). Because of the conditional nature of the signal (i.e., fluorescent signal is detected only after a fusion event), the incidence of false positives was significantly reduced. A fluorescence signal was deemed positive if it was localized to the nucleus (as a consequence of the H3.1 fusion protein), fluoresced above the background fluorescence of unaltered cocultures, and did not fluoresce with excitation/emission at alternate wavelengths. Under these criteria, transduction of the cells with each BiFC half alone did not yield a detectable false-positive signal (Supplemental Fig. S1B ).
Coculture protocol
The design of coculture experiments is illustrated in Supplemental Fig. S2A . In our study, we transduced MSCs with lentiviral particles expressing the BiFC complex amino terminus GFP, histone H3.1 (VNH3.1), and the breast epithelial cells (MCF10a) or breast cancer cells (T47D, MDA-MB-231, and MCF7), with the corresponding BiFC complex carboxyl terminus GFP, histone H3.1 (YCH3.1) (Supplemental Fig. S2A ). The histone H3.1 tagged to each construct brought the BiFC halves in close association in the nucleus. MSCs were mixed with each epithelial cell type (i.e., MSC with MDA-MB-231, MSC with T47D, MSC with MCF7, and MSC with MCF10a) in 4-well chamber slides, such that the stromal population was mixed with each epithelial cell type. The ratio of cells for cocultures was 80,000 MSCs to 35,000, 112,000, 100,000, and 90,000 MDA-MB-231, T47D, MCF7, and MCF10a cells, respectively. Cell densities were selected so that surface area coverage for each cell type was approximately 50% at 24 h after the cocultures were initiated (Supplemental Fig. S2B ). Forty-eight hours after coculturing began, the cells were fixed and stained with DAPI. Fusion products were identified by fluorescence microscopy. A signal (green fluorescence) was considered positive if it was stronger than the background in the FITC channel for unaltered cocultures, was nuclear (overlapped with DAPI), and did not (continued from previous page) green fluorescent protein; HepB, hepatitis B; HepC, hepatitis C; HPV, human papillomavirus; HSD, honest significant difference; MCF7, human breast cancer cells; MCF10a, mammary epithelial cells; MDA-MB-231, human breast adenocarcinoma cells; MSC, multipotent stromal/mesenchymal stem cell; NOD, nonobese diabetic; PtSer, phosphatidylserine; Rac, ras-related C3 botulinum toxin substrate; STR, short tandem repeat; T47D, human ductal breast epithelial tumor cell; VNH3.1, amino terminus GFP, histone H3.1; YCH3.1, carboxyl terminus GFP, histone H3.1; Z-VAD-FMK, carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone crossover to the rhodamine and cyanine (Cy)5 channels. The frequency of fusion products was reported relative to the total number of nuclei in at least 200 fields of view per experiment, with about 110 cells per field. We performed each experiment at least 3 times.
Hypoxic treatment
Hypoxic treatment was performed 16 h after the initiation of cocultures. The cocultures were removed from standard tissue culture conditions (21% O 2 , 5% CO 2 , and 74% N 2 ) and put in conditions of oxygen deprivation (2% O 2 , 5% CO 2 , and 93% N 2 ) for 3 h. At the end of coculturing (48 h after initiation) the cells were fixed and stained with DAPI, and the number of fusion products was recorded. We recognize that standard tissue culture conditions are actually hyperoxic relative to normal tissue, but for the purposes of this study, we considered the condition of 2% O 2 to be hypoxic.
Apoptotic cell treatment
Apoptosis was induced by treatment of T47Ds with 1 mM staurosporine (Sigma-Aldrich) for 12 h. Annexin V staining determined that 50-75% of the cells were apoptotic. Floating and attached cells were collected and used in the experiments. To investigate the involvement of apoptotic cells in cancer cell fusion, MSCs and T47Ds were transduced, and cocultures were initiated as described above. Sixteen hours after initiation of the cocultures, apoptotic cells were added at a ratio of 1 apoptotic cell for 2 coculture cells. The cocultures were analyzed under normoxic and hypoxic conditions, as described above.
Annexin V apoptosis assay
Breast epithelial cells exposed to low oxygen for 3 h were stained with the ApoAlertAnnexin V-FITC Apoptosis Kit (Clontech, Mountain View, CA, USA), in accordance with the recommendations of the manufacturer. Apoptotic cells were detected with a fluorescence microscope.
Caspase inhibitor treatment
Caspase activity was inhibited in cocultures of fusion partners by using the small molecule, Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone; Promega, Madison, WI, USA) and the ability of cells to fuse under normoxic and hypoxic conditions was analyzed. Z-VAD-FMK is a cell-permeable pan-caspase inhibitor that irreversibly binds to the catalytic site of caspase proteases and is widely used to inhibit apoptosis. In our study, each cell population (MSCs, T47D, and MCF7) was transduced with the lentiviral particles expressing the BiFC complex VNH3.1 for MSCs, and the corresponding BiFC complex YCH3.1 for T47Ds or MCF7s, as described above. Twelve hours after transduction, each cell population was treated with Z-VAD-FMK (1 mM) for 1 h, and the cocultures were initiated. The coculture medium was supplemented with Z-VAD-FMK during the entire experiment (36 h), and the cocultures were assessed under normoxic and hypoxic (2% O 2 , 5%CO 2 , and 93% N 2 ) conditions, with and without the addition of apoptotic cells. The cells were fixed and stained with DAPI, and the fusion products were recorded.
Time-lapse microscopy
Cocultures for time-lapse microscopy were initiated as described in the protocol above. In brief, MSCs were transduced with lentiviral particles from the BiFC component VNH3.1, and T47D or MCF7s were transduced with lentiviral particles from the BiFC component YCH3.1. At 48 h after initiation of the cocultures, the fusion products were identified by fluorescence microscopy (TE200; Nikon, Inc., Melville, NY, USA). The cells were maintained at 5% CO 2 , 37°C, in a humidified atmosphere. Phasecontrast and fluorescent images of hybrids were taken every 5 min for 3 h with a 320 objective (0.5 NA, plan fluor 320 phase 1). Images of double-transduced parental cells and of control cells were taken. The paths of migrating cells were analyzed by using the manual tracking and chemotaxis and migration tool in NIH Fiji software (ImageJ; National Institutes of Health, Bethesda, MD, USA) (27) . In brief, the center of a given nucleus was selected for each frame. Based on the resultant path created, the software was used to calculate velocity, total distance, and directionality.
For long-term tracking (72 h), MSCs and T47Ds were transiently transfected with mCherry-and GFP-expressing plasmids, respectively. Sixteen hours after transfection, the cocultures were initiated, and fusion products (expressing both red and green fluorescence) were identified 24 h later with a fluorescence microscope. Phase-contrast and green fluorescent images of hybrids were taken every 10 min for 72 h with a 310 objective in the Citation 3 imaging reader (Bio-Tek, Winooski, VT, USA). The cells were maintained at 5% CO 2 and 37°C, and the medium was replaced every 24 h. At 72 h, a static fluorescence image (green and red) of the tracked hybrid was obtained to confirm the hybrid's identity.
Statistical analysis
All data are presented as means 6 SD. When 2 groups were compared, a 2-tailed Student's t test was used. When more than 2 groups were compared, ANOVA with Tukey's honest significant difference (HSD) post hoc test was used. P , 0.05 denoted statistically significant differences.
RESULTS
Breast tumor cells fuse with MSCs spontaneously
Fusion between tumor cells and host cells has been shown by several studies, many of which implicate bone marrow-derived cells of myeloid lineage as host fusion partners [reviewed in (17, 28) ]. We propose that fusion of tumor cells with cells of the stroma gives rise to hybrid cells capable of dissemination and new tumor growth. In the initial step of investigating the role of cell fusion in breast cancer metastasis, we examined the ability of MSCs to fuse spontaneously with breast cancer cells with different degrees of aggressiveness (T47D cells, which are nonmetastatic, and MDA-MB-231 cells, which are metastatic) and nontumorigenic MCF10a breast epithelial cells . We have developed a powerful tool for the detection of fusion products in vitro that uses BiFC (see Materials and Methods and Supplemental Fig. S1A) . Because of the conditional nature of the signal, the incidence of false positives is significantly reduced. Moreover, transduction of the cells with each BiFC half did not yield any detectable false positives (Supplemental Fig. S1B ). Lentiviral particles expressing each half of the BiFC complex were delivered to the cells, and cocultures were initiated as described in Materials and Methods (Supplemental Fig. S2A ). Fusion products were identified with an epifluorescence microscope. The MSCs fused spontaneously with all breast epithelial cell types (Fig. 1A and Supplemental Fig. S3A ) at a fusion rate of ;1:1000 for cancer cell types and ;1:2000 for the nontumorigenic cell line, MCF10a (P , 0.05) (Fig. 1B  and Supplemental Fig. S3B ).
Fusion is enhanced with hypoxia
To test whether the rate of fusion could be regulated by factors associated with tumor microenvironments, we evaluated the effect of hypoxia (29) . This hypoxic microenvironment puts cancer cells under stress and may promote their fusion with cells of the stroma recruited to the tumor microenvironment, as a means of survival. Cells were transduced with lentiviral particles expressing each half of the BiFC complex, and cocultures were initiated between MSCs and breast epithelial cells. The cocultures were subsequently exposed to low oxygen for 3 h, and fusion products were recorded, as described in Materials and Methods. We found that hypoxia stimulates a significant increase in fusion between MSCs and the T47D nonmetastatic breast cancer cells (P , 0.05; Fig. 1C ). This increase in fusion was not restricted to T47Ds, but was also observed with the nonmetastatic MCF7 cancer cells (P , 0.05; Supplemental Fig. S3B ).
Fused breast tumor cells show increased migratory capability
To study the contribution of spontaneous cell fusion to metastasis, we used time-lapse microscopy to analyze the migratory capability of hybrids derived from the fusion between T47Ds and MSCs. Cocultures were initiated between the MSCs and the T47Ds. Forty-eight hours after the initiation of the cocultures, the hybrids were identified and tracked every 5 min for 3 h with an inverted fluorescence microscope. The MSCs were highly motile and showed directed travel patterns. The T47Ds were 3 times less motile and showed little directional travel. The hybrids acquired the enhanced motility of the MSC parent, but were nondirectional, similar to their T47D breast cancer cell parent ( Fig. 2A, B) . The same trend in motility and directionality was observed in hybrids between MCF7s and MSCs (Fig. 2C, D) .
The mechanism of fusion of breast cancer cells involves apoptosis
Given its potential relevance in breast cancer metastasis, it is critical to understand the mechanisms governing cell fusion. In the experiments described above, we noted that hypoxia had little impact on the ability of MDA-MB-231 metastatic cancer cells to fuse spontaneously with MSCs. This observation suggests that hypoxia promotes fusion of nonmetastatic cancer cells with MSCs and therefore enables metastasis, an event that is not necessary or advantageous for the already metastatic MDA-MB-231 cells. A recent study identified signaling via the phosphatidylserine (PtdSer) receptor brain-specific angiogenesis inhibitor (BAI)-1 as a cue to promote fusion of healthy myoblasts, involving the ELMO/Dock180/Rac1 pathway (18) . Blocking apoptosis potently impaired myoblast fusion, and adding back apoptotic myoblasts restored fusion. The added apoptotic myoblasts exposed PtdSer, but did not attach to the tissue culture plate or fuse on their own. They were necessary to promote myoblast fusion, requiring PtdSer-dependent cell-cell contact between apoptotic and viable myoblasts (18) . Because apoptosis is increased in certain cell types in hypoxic conditions [reviewed in (30) ], we tested whether the same would be true of the breast epithelial cells used in this study. In fact, apoptosis was enhanced by hypoxia (2% O 2 , 3 h) only in the T47D and MCF7 nonmetastatic cancer cells (Fig. 3) . Because we found that hypoxia considerably increases fusion between MSCs and the T47D and MCF7 breast tumor cells but not between MSCs and MDA-MB-231s or MCF10as (Fig. 1C and Supplemental Fig. S3B ), we investigated first whether apoptosis is involved in the fusion of cancer cells. Cocultures between MSCs and T47Ds were initiated as described in Materials and Methods. Sixteen hours after initiation of cocultures, they were supplemented with T47D apoptotic cells, and fusion products were recorded. We found that addition of apoptotic cells to cocultures significantly increased cell fusion between MSCs and T47Ds in normoxic and hypoxic conditions (P , 0.05; Fig. 4A) . To continue the investigation of the role of apoptosis in cancer cell fusion, we assessed whether inhibition of apoptosis impairs cell fusion. Apoptosis was inhibited in the fusion partners before coculture initiation with the pan-caspase inhibitor Z-VAD-FMK (1 mM). The inhibitor remained in the coculture medium during the entire coculture experiments and did not seem to affect the morphology or viability of the cells. We analyzed the ability of MSCs and T47D to fuse in normoxic and hypoxic conditions. We found that inhibition of apoptosis reduces cell fusion in normoxic conditions, and this reduction was significant in hypoxic conditions (P , 0.05), whereas addition of apoptotic cells rescued the fusion diminished by the pan-caspase inhibitor (Fig. 4A) . Apoptosis appeared also to regulate the fusion of nonmetastatic MCF7s and MSCs (Fig. 4B) , suggesting that the mechanism by which cancer cells fuse with MSCs involves apoptosis.
DISCUSSION
Our findings describe a novel mechanism by which cancer cells fuse with MSCs, an event that could underlie the development of metastases. The breast cancer cells fused spontaneously with the MSCs. This fusion was significantly enhanced by hypoxia, especially between the nonmetastatic breast cancer cells and MSCs, and was considerably increased by apoptosis. In addition, the hybrids formed showed a significantly higher migratory capability, lending support to the prediction that fusion contributes to cancer metastasis.
The possibility that cell fusion gives rise to the metastatic phenotype was first put forward nearly a century ago by Aichel (1) and later by Mekler (31) and Goldenberg (32) . In recent years, this hypothesis has gained further support. Spontaneous fusion has been reported between normal breast epithelium and breast cancer cells (33) (34) (35) (36) , among breast tumor cells themselves (37) (38) (39) , between breast cancer epithelium and endothelial cells (40) , and between breast cancer epithelium and tumor stromal cells (12, 13) . In vitro studies of hybrids formed between normal breast epithelium (M13SV1-EGFP-Neo) and breast cancer cells (HS578T-Hyg) showed increased locomotory activity, compared with the normal parental lines. This fusionenhanced migration was associated with altered chemokine ligand (CCL)21/chemokine receptor (CCR)-7 signaling, which has been linked to the metastatic spread of breast cancer to lymph nodes (34) . Increased metastatic potential of hybrids was also observed in vivo when breast cancer cell variants (MDA-MB-231) with tropism for either lung or bone injected in nude mice gave rise to hybrids capable of metastases to both organs (37) . Drug susceptibility was also found to be altered in hybrids. Hybrids formed between parental breast cancer cells (MCF-7), with and without resistance to doxorubicin, were heterogeneous, with some exhibiting resistance and others not (39) . Likewise, hybrids derived from breast epithelial cells (M13SV1-EGFP-Neo) and breast cancer cells (MDA-MB-435-Hyg) showed altered sensitivity to the PI3K inhibitor, Ly294002, as a consequence of differential RAF-AKT crosstalk among hybrids (36) . Close probing of the heterogeneity generated by the formation of stromal cell-breast cancer cell hybrids indicated that hybrids can undergo DNA ploidy reduction and morphologic switching from mesenchymal-like to breast carcinoma-like. In addition, analysis of coding single-nucleotide polymorphisms by RNA sequencing showed genetic contributions from both fusion partners in the primary tumor and metastases (41) .
Spontaneous fusion was also reported with other cancer cell types. A study showed that mesenchymal stem cells could spontaneously fuse with lung cancer cells in vitro. Fusion was also detected in vivo when freshly mixed lung cancer cells and MSCs were xenografted by subcutaneous injection into nonobese diabetic (NOD)/SCID immunodeficient mice (42) . The hybrids formed acquired increased motility and invasiveness and were found to contribute to highly malignant subpopulations with both epithelial-to-mesenchymal and stem cell-like properties (42) . In addition, cells of a melanoma clone (wild-type for tyrosinase, C/C) implanted into BALB/c nu/nu mice (homozygous mutation for albino tyrosinase, c/c) developed massive pulmonary metastases a few weeks later. Analysis of chromosomes of cells from the metastatic tumors showed that most clones had acquired the c allele (same as that of the BALB/c recipient) while maintaining the C allele. Thus, lung metastases primarily comprised host-tumor hybrids and it is interesting that these hybrids expressed the same traits of enhanced motility and MSH/BMX responsiveness as in vitro-derived melanomamacrophage hybrids (4) .
Clinical studies have confirmed the presence of cell fusion in tumors as well, as found in patients who had undergone hematopoietic stem cell transplantation, with subsequent development of tumors showing evidence of donor genes in their cells (22, 43) . In addition, a new report used STR polymorphism and forensic genetic techniques to suggest that a metastatic melanoma lesion in a patient arose from the fusion between a bone marrow-derived cell the patient received as a transplant and a tumor cell (44) .
Our findings are in line with those in previous studies supporting the notion that cell fusion contributes to the ability of cancer cells to disseminate and perhaps metastasize. Moreover, a previous study showed that the motilityassociated integrin subunits a2, a3, a5, a6, av, b1, and b3, which are involved in the migration of leukocytes and cancer cells, were significantly upregulated in metastatic macrophage-melanoma hybrids compared with parental melanoma cells (45) . A more recent study also indicated that fusion between cancer cells (ovarian and lung) and hematopoietic cells of the myeloid lineage gave rise to hybrids expressing significantly higher levels of the promigratory marker CXC chemokine receptor (CXCR)-4, which was conferred by the parental myeloid cells (46) . Collectively, the increase in motility-associated integrin subunits and CXCR4 levels in hybrids may equip them with superior migratory potential and help their dissemination to various secondary organs, therefore explaining how fusion could provide a means by which adherent cancer cells acquire new qualities necessary to form metastases (i.e., enhanced motility and matrix degradation) under conditions conducive to hematopoietic survival and later resume tumorlike activities (i.e., rapid proliferation) under conditions conducive to epithelial survival. Cancer cell fusion may also provide a nonmutational mechanism that could contribute to aberrant gene expression patterns and give rise to highly malignant subpopulations with properties of cancer stem cells.
In contrast, a study showed that fusion between hematopoietic stem cells and human esophageal cancer cells slowed the growth speed of esophageal cancer cells and decreased the clone formation ability and tumorigenicity in NOD/SCID mice (47) . So far, only the tumorigenicity of some hybrids that were formed in vitro between normal epithelial cells or fibroblasts and tumorigenic cancer cells has been shown to be generally suppressed compared to the parental cancer cells (48) (49) (50) , probably because of activation of some tumor-suppressor genes, although some exceptions to this observation have been shown (20) . The hybrids obtained in this way may deserve in depth analyses to understand the involvement of fusion in their tumor suppressor phenotype.
MSCs are known to be present in both healthy and cancerous breast tissue (51, 52) and have even been observed trafficking directly from bone marrow to sites of primary breast tumors (53) . These studies have implicated MSCs in encouraging the migration and metastasis of primary tumors, primarily through MSC secretion of chemotactic cytokines such as CCL5. Our results suggest that cell fusion may be an additional mechanism by which MSCs encourage breast cancer metastasis.
Although cell fusion occurs naturally in many fundamental biologic processes [homotypic fusion of myoblasts, placental trophoblasts (21) , and macrophages (21, 54) and heterotypic gamete fusion (21) ] and some pathologic conditions [viral-mediated fusion (55)], the mechanisms by which this phenomenon occurs are poorly understood, especially in the context of cancer. Studies have shown that cancer cell fusion can be induced by viruses (2, 56) or cellcell invasion mechanisms of cellocytosis (cell-cell internalization) (54, 57) or entosis (a nonapoptosis cell death mechanism) (58) . A recent work, however, identified apoptotic cells as a new type of cue that induces signaling via the PtdSer receptor BAI1 to promote fusion of healthy myoblasts (18) . The 7-transmembrane protein BAI1 (a member of the adhesion type GPCR family) mediates recognition of PtdSer on apoptotic cells and signals through the ELMO/Dock180/Rac1 pathway to enhance mammalian myoblast fusion. In that study, blocking apoptosis potently impaired myoblast fusion, and adding back apoptotic myoblasts restored it (18) . Our findings are consistent with those in that study, as addition of apoptotic cells significantly increased cell fusion between MSCs and T47D breast cancer cells. We also observed reduction of cell fusion when apoptosis was inhibited, but this reduction was rescued by supplementation of Z-VAD-FMK-treated cocultures with apoptotic cells. It has been shown that myoblasts and macrophages use some of the same molecular components in fusion, including the Dock180 protein (59) , suggesting that PtdSer-BAI1 signaling is used by other cell types for fusion in addition to myoblasts. Moreover, BAI1 is well expressed in other cell types, including breast cancer cells and bone marrow-derived cells. These findings, together with our data, indicate that the mechanism by which cancer cells fuse with MSCs can involve apoptosis and may operate via PtdSer-BAI1 signaling.
We therefore propose that hypoxia-induced apoptosis in primary tumors stimulates cell fusion between MSCs and tumor cells, resulting in hybrids that exhibit both parental properties (mobility and proliferation) that enable their dissemination and new tumor growth at distant sites or metastases. In vivo studies addressing whether metastasis can in fact be initiated by fusion of cancer cells will complement this study. Investigating the involvement of BAI1 in cancer cell fusion will help delineate the molecular mechanisms of fusion of cancer cells and potentially the mechanisms of metastasis development. In the long run, this study may provide new strategies for developing alternate drugs for cancer treatment and preventing metastatic spread.
